Navigation Links
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Date:7/22/2009

ainst the drug itself, thereby lessening the potential for immunological side effects and neutralization of the treatment effect. As a fully human antibody, r84 may also have better pharmacokinetic properties in patients.

About Affitech A/S

Affitech A/S is an antibody research and development company. It was formed recently by a reverse merger of Norway, Oslo-based Affitech AS with Pharmexa A/S, a Danish biotech company. The merged company has developed several proprietary technology platforms that constitute a highly productive, fully human, antibody discovery engine. Based on its proprietary technologies and know-how, Affitech has built a pipeline of promising human antibody candidates for internal development or co-development with collaboration partners. The focus of the newly expanded company is to pursue both research and clinical development of antibody therapeutic products. Further information can be found at www.affitech.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historic
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.; Affitech A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...EAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics In... in a randomized Phase 2B study of AEG35156, a tar...nt for multiple oncology indications. ,, The st...udy of the X-Linked Inhibitor of Apoptosis (XIAP) ...dose Cytarabine and Idarubicin in AML Following Fa...
(Date:11/18/2009)... Calif., Nov. 18 Marrone Bio Innov...nt and commercialization of effective and environm...unced that it has been named an IC20 company by th... largest national angel investing group. ,, Com...ing to rewarding results for all stakeholders, inc...
(Date:11/18/2009)...MOND, Calif., Nov. 18 Sa... today that data from the University of Pennsylvan...Sangamo,s zinc finger nuclease (ZFN) based product...ematurely disclosed on the internet. ,, Data we... of Pennsylvania School of Medicine from a single ...
(Date:11/18/2009)...SAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM Bio...sciences product development company that identifi...ancer-related products at various stages of develo...ing nimotuzumab were presented today in a poster a...ncer Therapeutics conference in Boston, Massachuse...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...est Michigan Science & Technology Initiative t... and approve applications from life science compan...Capital Fund. The Michigan Pre-Seed Capital Fund ...ech, high-growth start-up companies in four techno...nd materials; alternative energy; homeland securit...
... ImmunoVaccine Technologies Inc. (IVT), a,vaccine ... agreement with the,National Research Council Inst...collaboration will develop new 3-D MRI technology ...y on reducing tumour growth. , "This research ...RI,analysis, down to the individual cell level, an...
...CODE genetics,(Nasdaq: DCGN ) today announced tha... laboratory, which processes the company,s deCODEm...agnostic tests for several common,diseases, has be...sts (CAP),following a recent inspection. The U.S. ...as granted the CAP Laboratory Accreditation Progra...
Other Biology Technology:The West Michigan Science & Technology Initiative is Named Statewide Reviewer for Life Science Funding Requests Through New Program 2The West Michigan Science & Technology Initiative is Named Statewide Reviewer for Life Science Funding Requests Through New Program 3ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4
(Date:11/20/2009)..., Mich.---We,ve all read studies about the health ...is true at the molecular level, where amino acids ...age when single than when paired up with other cys...Michigan, along with colleagues in Belgium, have d...ingle cysteines. The research appears in the Nov. ...
(Date:11/20/2009)...ago, a group of University of Oklahoma researchers...t of the human genome project. Today, the OU Adv... to an international effort to sequence the tomato...ational Science Foundation for plant genomics. , ...e, so improving the tomato and crop yields will im...
(Date:11/20/2009)...gton, DC Nov. 20, 2009) Scientists from the Mari...ions of the Naval Research Laboratory (NRL) organi...ientists on an Arctic expedition to initiate metha...ermine the spatial variation of sediment contribut...S. Coast Guard Cutter Polar Sea as a research plat...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2NSF awards $7.5M grant to University of Oklahoma for plant genomics 2International expedition investigates climate change, alternative fuels in Arctic 2Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 1Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 2Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 3Boston Scientific PROMUS 28R 29 and First Generation TAXUS 28R 29 Express 28R 29 Stents Continue Excellent Performance in SPIRIT III Trial 57889 4KATE AND CASSIE CARE 21 This Harvest Season Charity Reaps the Benefits of Kate 26 Cassie wines 57888 1KATE AND CASSIE CARE 21 This Harvest Season Charity Reaps the Benefits of Kate 26 Cassie wines 57888 2Fortebio Inc to Present at UBS Global Life Sciences Conference 14190 1
...09 University College London Business PLC (UCLB) ...harmaceutical company, announced the signing of an...1V and all assets and technologies related to the ...alopathy (AHE). , The compound recently demonst...onia, a highly toxic chemical that builds up durin...
...ored as the 2009 recipient of the Signature Genomi...e of Medical Genetics (ACMG) 2009 Annual Clinical ...irector, Cytogenetics and Molecular Genetics at th... Dr. Chun received her PhD from the University of ...he Signature Genomics Travel Award is given to a s...
...es Pioneer Awards will be presented on April 3 at ...The awards honor two recipients who have contribut...ound. The clinical science award will be presented... of Medicine at the University of California in Lo...l be presented to Ernest Feleppa, PhD, director of...
Other Biology News:Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB 2Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB 3AIUM Presents 2009 Joseph H. Holmes Pioneer Awards 2
...ressurized perfusion system for small volumes of p...ochemistry, or general liquid-handling research ap... of precious drugs. Switch between four or eight s...ize cross-contamination with BackStop back-flow pr...
Sma I (High Concentration) from Takara Mirus Bio
pSTBlue-1 AccepTor Vector Kit from Novagen
...0 is a compact, highly versatile power supply. Cap...s, this power supply is ideal for PAGE, SDS-PAGE, ...small format transfer apparatus. It is designed to...ith a continuously variable output in either mode....
Biology Products: